

**Results from PPL20 which was ended prematurely after 22 months due to slow recruitment when only 2 out of 15 patients had completed the treatment schedule.**

Data posted on [www.clinicaltrialsregister.eu](http://www.clinicaltrialsregister.eu)

**Demographics and Other Baseline Characteristics**

Table 1 Age (years), gestational age (weeks + days)					
SUBJID	Group	Subject age	Gestational Age, weeks	Gestational Age, Days	
01-1003	Active	36	33	5	
01-1004	Active	31	26	1	
02-1001	Active	33	31	1	
02-1002	Active	32	31	0	
02-1003	Active	36	26	5	
02-1004	Active	40	28	3	
02-1005	Active	33	31	5	
02-1006	Active	40	30	3	
02-1009	Active	31	31	4	
02-1010	Active	38	30	1	
01-1002	Control	39	32	4	
02-1008	Control	27	28	4	
01-1001	Not Randomised	27	27	0	
01-1005	Not Randomised	.	30	2	
02-1007	Not Randomised	49	29	1	
Active	N	10	10	10	
	Missing	0	0	0	
	Min	30.67	26.00	0.00	
	Median	34.72	30.50	3.00	
	Max	40.27	33.00	5.00	
	Mean	35.05	29.70	2.80	
	Std	3.57	2.31	1.93	
Control	N	2	2	2	
	Missing	0	0	0	
	Min	27.42	28.00	4.00	
	Median	33.38	30.00	4.00	
	Max	39.34	32.00	4.00	
	Mean	33.38	30.00	4.00	
	Std	8.43	2.83	0.00	
NR	N	2	3	3	
	Missing	1	0	0	

Table 1 Age (years), gestational age (weeks + days)				
SUBJID	Group	Subject age	Gestational Age, weeks	Gestational Age, Days
	Min	26.81	27.00	0.00
	Median	38.00	29.00	1.00
	Max	49.19	30.00	2.00
	Mean	38.00	28.67	1.00
	Std	15.83	1.53	1.00

### Vital signs by subject at screening

Table 2 Weight, height and heart rate (HR) by subject.							
Subject	Group	WEIGHT		HEIGHT		HR	
		Baseline	Screening	Baseline	Screening	Baseline	Screening
01-1001	Not randomised	.	90	.	163	.	76
01-1002	Standard of Care	68	69	166	166	76	75
01-1003	Tafoxiparin+Standard of Care	.	60	.	160	.	90
01-1004	Tafoxiparin+Standard of Care	50	54	160	160	60	91
01-1005	Not randomised	.	57	.	170	.	87
02-1001	Tafoxiparin+Standard of Care	67	68	166	166	67	98
02-1002	Tafoxiparin+Standard of Care	68.5	68.5	162	162	85	96
02-1003	Tafoxiparin+Standard of Care	.	102	.	176	.	83
02-1004	Tafoxiparin+Standard of Care	.	61	.	162	.	75
02-1005	Tafoxiparin+Standard of Care	.	67	.	163	.	105
02-1006	Tafoxiparin+Standard of Care	.	82	.	160	.	77
02-1007	Not randomised	70	66	160	160	87	85
02-1008	Standard of Care	.	76	.	165	.	62
02-1009	Tafoxiparin+Standard of Care	.	94	.	168	.	70
02-1010	Tafoxiparin+Standard of Care	.	80	.	155	.	75

## Measurements of Treatment Compliance

Treatment compliance was reported with the number of IMP-doses taken. According to the study protocol the maximum number of possible dose administrations were up to 28 administrated as once daily injections of 90 mg of tafoxiparin.

## Extent of Exposure

Table 3		Study medication given.																											
Subject	Group	Visit																											
		2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29
01-1002	Control	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
01-1003	Active	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
01-1004	Active	No	Yes	Yes	Yes	Yes	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1001	Active	Yes	Yes	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1002	Active	Yes	Yes	Yes	Yes	Yes	Yes	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1003	Active	No	Yes	Yes	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1004	Active	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1005	Active	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
02-1006	Active	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
02-1008	Control	N/A	N/A	N/A	N/A	N/A	N/A	N/A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1009	Active	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1010	Active	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

Three patients enrolled (01-1001, 01-1005, 02-1007) was never randomized to treatment

# 1 EFFICACY EVALUATION

The primary objective of this efficacy evaluation was to assess the safety impact of the study medication on the enrolled patients. Only three patients received more than 7 doses (criteria for patient replacement at the discretion of the Sponsor). These three patients were considered for efficacy evaluation.

## Efficacy Results and Tabulations of Individual Subject Data

Table 4 Selected data by subject and visit. Source: Statistical Analyses			Visit number (see Feil! Fant ikke referansekinden. for visit labels)																																							
Subject	Group	Variable	1 Screening	2 Base-line	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30 Post de-livery within 24h	31 At dis- charge	33 Follow-up (8±1 week after discharge) <sup>8</sup>								
02-1004	Active	Medication	.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	.	.	.				
02-1004	Active	Cardiac Output	.	3.6	5	.	.	.	.	.	4.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6	2.9			
02-1004	Active	DBP	92	92	94	88	94	93	95	96	90	85	87	84	98	93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	134	88	85		
02-1004	Active	SBP	144	144	146	142	148	134	139	150	137	130	134	128	150	140	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	216	149	133		
02-1004	Active	PIGF	.	19.5	19.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.			
02-1004	Active	sFlt-1	.	16940	47470	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.			
02-1004	Active	sFlt-1/PIGF ratio	.	868.7	2459.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.			
02-1004	Active	Stroke volume	.	47	55	.	.	.	.	.	51	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	69	41		
02-1004	Active	Uterine artery resistance index	.	0.75	.	.	.	.	.	.	0.80	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
02-1004	Active	Study completed	.	Yes (Days in study = 70)																																						
02-1004	Active	Delivery information	.	2022-12-27 / 30+3 / Spontaneuos=No / Caesarean (HELLP syndrome)																																						
02-1005	Active	Medication	.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	.	.	.
02-1005	Active	Cardiac Output	.	6	4.6	.	.	.	.	.	4.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.1	3.6
02-1005	Active	DBP	87	87	82	76	83	70	68	68	89	85	94	94	87	68	72	80	82	84	76	82	93	89	85	84	86	89	74	85	86	90	59	75	.	.	.	.	.	.	.	.
02-1005	Active	SBP	131	131	131	120	121	122	127	127	135	135	130	130	134	115	130	129	118	117	123	136	134	128	138	129	133	129	133	129	125	140	107	110	.	.	.	.	.	.	.	.
02-1005	Active	PIGF	.	429.7	303.6	.	.	.	.	.	223.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1005	Active	sFlt-1	.	1497	2434	.	.	.	.	.	3978	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
02-1005	Active	sFlt-1/PIGF ratio	.	3.5	8	.	.	.	.	.	17.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
02-1005	Active	Stroke volume	.	53	52	.	.	.	.	.	40	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	56	38

Table 4 Selected data by subject and visit. Source: Statistical Analyses			Visit number (see Feil! Fant ikke referansekinden. for visit labels)																													30	31	33							
Subject	Group	Variable	1 Screening	2 Base-line	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	Post de-livery within 24h	At dis-charge	Follow-up (8±1 week after discharge) <sup>8</sup>							
02-1005	Active	Uterine artery resistance index		0.40	.	.	.	.	.	.	0.49	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.39	.	.	.	.	.	0.45	.	.	.
02-1005	Active	Study completed	Yes (Days in study = 91)																																						
02-1005	Active	Delivery information	2023-02-22 / 36+4 / Spontaneuos=Yes / .																																						
02-1006	Active	Medication	.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	.	.	.			
02-1006	Active	Cardiac Output		6.2	5.8	.	.	.	.	.	.	.	.	.	.	.	.	.	5.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.8	.	5.2	4.5
02-1006	Active	DBP	88	88	78	74	80	68	88	85	89	85	75	78	84	84	72	78	72	72	90	71	85	89	82	88	78	82	82	90	79	70	80	70							
02-1006	Active	SBP	133	133	138	135	133	129	144	138	131	135	138	128	133	131	131	122	123	123	138	123	133	129	124	130	125	132	137	143	129	165	134	130							
02-1006	Active	PIGF		85.7	86.9	.	.	.	.	.	.	.	.	.	.	.	.	.	65.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	75.8	.	.	.
02-1006	Active	sFlt-1		3334	2355	.	.	.	.	.	.	.	.	.	.	.	.	.	2564	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5623	.	.	.	
02-1006	Active	sFlt-1/PIGF ratio		38.9	27.1	.	.	.	.	.	.	.	.	.	.	.	.	.	39.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	74.2	.	.	.	
02-1006	Active	Stroke volume		80	69	.	.	.	.	.	.	.	.	.	.	.	.	.	70	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	65	.	65	59	
02-1006	Active	Uterine artery resistance index		0.79	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.58	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.21	.	.	.	
02-1006	Active	Study completed	Yes (Days in study = 111)																																						
02-1006	Active	Delivery information	2023-08-15 / 37+1 / Spontaneuos=No / Instrumental (Maternal Indication)																																						

## Primary Safety Endpoint

Table 5 Adverse events. None of the adverse events were serious (SAE).

Subject	Group	Baseline	Category	Adverse event	Start	Severity	Relation	Outcome	Stop
01-1002	Standard of Care	2021-10-13	Mother	headache	2021-10-19	Mild	.	Resolved	2021-10-23
01-1002	Standard of Care	2021-10-13	Infant	tachypnea	2021-10-23	Moderate	Unrelated	Resolved	2021-10-24
01-1004	Tafoxiparin+Standard of Care	2022-02-10	Mother	pre-eclampsia	2022-02-16	Moderate	Unrelated	Resolved	2022-02-16
02-1001	Tafoxiparin+Standard of Care	2022-09-13	Mother	Anemia	2022-09-18	Mild	Unrelated	Resolved	2022-06-15
02-1001	Tafoxiparin+Standard of Care	2022-09-13	Mother	Liver dysfunction (elevated ALT)	2022-11-11	Mild	Unlikely	Unknown	.
02-1001	Tafoxiparin+Standard of Care	2022-09-13	Infant	Respiratory distress	2022-09-15	Mild	Unrelated	Resolved	2022-10-17
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	Anemia	2022-09-20	Moderate	Unrelated	Resolved	2022-09-21
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	thrombocytopenia	2022-09-17	Moderate	Unlikely	Resolved	2022-09-24
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	severe hypertension	2022-09-19	Moderate	Unlikely	Resolved	2022-09-20
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	hypoalbuminaemia	2022-09-20	Mild	Unlikely	Resolved	2023-01-24
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Infant	Respiratory distress	2022-09-19	Mild	Unrelated	Resolved	2022-10-18
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	HELLP syndrome, hypertensive crisis	2022-12-26	Severe	Unrelated	Resolved	2023-02-21
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	low platelet count	2022-12-20	Mild	Unlikely	Resolved	2023-02-21
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	Elevated AST and ALT	2023-02-21	Mild	Possible	Not resolved	.
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	Low albumine	2022-12-27	Mild	Unrelated	Resolved	2023-02-21
02-1005	Tafoxiparin+Standard of Care	2023-01-20	Mother	hyperkalaemia	2023-01-30	Mild	Unlikely	Resolved	2023-01-30
02-1005	Tafoxiparin+Standard of Care	2023-01-20	Mother	absence of amniotic fluid	2023-02-17	Mild	Possible	Resolved	2023-02-22
02-1005	Tafoxiparin+Standard of Care	2023-01-20	Mother	Low total protein	2023-02-23	Mild	Unrelated	Resolved	2023-04-21
02-1008	Standard of Care	2023-07-20	Mother	preeclampsia	2023-07-21	Moderate	Unrelated	Resolved	2023-07-26

Other safety variables relevant for the Primary Safety endpoint are described below.

The exploratory endpoint was: *“The data from the secondary (efficacy) end-points will undergo a review with the purpose to establish a relevant composite efficacy end-point based on a combination of a selection of the current efficacy end-points. The selection of the individual endpoints to be included in the composite end-point will be guided by statistical evaluations of different combinations”*

This could not be performed due to lack of relevant data.

## SAFETY EVALUATION

All safety analyses were performed with the Safety Population (SAF).

### Adverse Events (AEs)

AEs are summarized enclosed

No SAEs are reported in the study

### *Brief summary of AEs*

#### Summary of AEs

In total 19 AEs were reported in total, i.e. 3 in Standard of care group and 16 AEs in Tafoxiparin group. (16 AEs in mothers and 3 AEs in infants). No injection site reactions were reported. See Table 6 below

Table 6

Subject	Group	Baseline	Category	Adverse event	Severity	Relation
01-1002	Standard of Care	2021-10-13	Mother	headache	Mild	.
01-1002	Standard of Care	2021-10-13	Infant	tachypnea	Moderate	Unrelated
01-1004	Tafoxiparin+Standard of Care	2022-02-10	Mother	pre-eclampsia	Moderate	Unrelated
02-1001	Tafoxiparin+Standard of Care	2022-09-13	Mother	Anemia	Mild	Unrelated
02-1001	Tafoxiparin+Standard of Care	2022-09-13	Mother	Liver dysfunction (elevated ALT)	Mild	Unlikely
02-1001	Tafoxiparin+Standard of Care	2022-09-13	Infant	Respiratory distress	Mild	Unrelated
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	Anemia	Moderate	Unrelated
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	thrombocytopenia severe	Moderate	Unlikely
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	hypertension	Moderate	Unlikely
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Mother	hypoalbuminaemia	Mild	Unlikely
02-1002	Tafoxiparin+Standard of Care	2022-11-13	Infant	Respiratory distress	Mild	Unrelated
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	HELLP syndrome, hypertensive crisis	Severe	Unrelated
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	low platelet count	Mild	Unlikely
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	Elevated AST and ALT	Mild	Possible
02-1004	Tafoxiparin+Standard of Care	2022-12-13	Mother	Low albumine	Mild	Unrelated
02-1005	Tafoxiparin+Standard of Care	2023-01-20	Mother	hyperkalaemia	Mild	Unlikely
02-1005	Tafoxiparin+Standard of Care	2023-01-20	Mother	absence of amniotic fluid	Mild	Possible
02-1005	Tafoxiparin+Standard of Care	2023-01-20	Mother	Low total protein	Mild	Unrelated
02-1008	Standard of Care	2023-07-20	Mother	preeclampsia	Moderate	Unrelated

## Clinical Laboratory Evaluation

### *Listing of Individual Laboratory Measurements by Patient and Each Abnormal Laboratory Value*

Blood samples were collected for laboratory determination of hematology and clinical chemistry at baseline. Values that were outside of the reference range and whether “Clinically significant” were flagged.

### *Evaluation of Each Laboratory Parameter*

Clinically significant abnormal laboratory results are discussed in the sections below

Tabulated individual data are listed in section 14. Data outside the reference range are highlighted in yellow.

### *Clinical Chemistry*

Table 7 below show which data were collected. In the subjects who received at least one dose of tafoxiparin, several hundred clinical chemistry tests were performed. Six of these were assessed as Clinically Significant outside the reference values (marked yellow in table 16), but none occurred during treatment or were of major significance.

Variable	Abbreviation
Alanine transaminase	ALT
Aspartate transaminase	AST
Albumin	ALB
Bilirubin (total)	BILIT
Bilirubin (direct)	BILIC
Alkaline phosphatase	ALP
Potassium	POT
Sodium	SOD
Urea	UREA
Total protein	TPROT
Creatinine	CREA
Calcium	CALC

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table.

Data outside the reference range and assessed as clinically significant are marked **red**.

Subject	Group	Variable abbrev.	Visit									
			1	8	11	15	18	22	29	30	31	33
01-1001	Not Randomised	ALT	153	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	ALT OR	Yes	.	.	.	.	.	.	.	.	.

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked red.

Subject	Group	Variable abbrev.	Visit										
			1	8	11	15	18	22	29	30	31	33	
01-1001	Not Randomised	ALT CS	Yes	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	AST	175	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	AST OR	Yes	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	AST CS	Yes	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	BILIT	0.9	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	CALC	8.4	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	CREA	0.39	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	POT	4.1	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	SOD	139	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	TPROT	5.9	.	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	ALB	32.4	.	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	ALB OR	Yes	.	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	ALB CS	No	.	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	ALP	169	196	.	.	.	.	.	190	175	90	.
01-1002	Standard of Care	ALP OR	Yes	Yes	.	.	.	.	.	Yes	Yes	Yes	.
01-1002	Standard of Care	ALP CS	No	No	.	.	.	.	.	No	No	.	.
01-1002	Standard of Care	ALT	18	19	.	.	.	.	.	20	51	23	.
01-1002	Standard of Care	ALT OR	.	.	.	.	.	.	.	.	Yes	Yes	.
01-1002	Standard of Care	ALT CS	.	.	.	.	.	.	.	.	No	.	.
01-1002	Standard of Care	AST	19	21	.	.	.	.	.	29	37	18	.
01-1002	Standard of Care	AST OR	.	.	.	.	.	.	.	.	Yes	Yes	.
01-1002	Standard of Care	AST CS	.	.	.	.	.	.	.	.	No	.	.
01-1002	Standard of Care	BILIC	.	0.1	.	.	.	.	.	.	.	.	0.1
01-1002	Standard of Care	BILIC OR	.	.	.	.	.	.	.	.	.	Yes	.
01-1002	Standard of Care	BILIC CS	.	.	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	BILIT	.	0.2	.	.	.	.	.	.	.	.	0.2
01-1002	Standard of Care	BILIT OR	.	.	.	.	.	.	.	.	.	Yes	.
01-1002	Standard of Care	CALC	8.8	8.9	.	.	.	.	.	8.8	9	.	.
01-1002	Standard of Care	CREA	0.77	0.73	.	.	.	.	.	.	0.63	.	.
01-1002	Standard of Care	POT	5.2	5.2	.	.	.	.	.	4.7	4.8	.	.
01-1002	Standard of Care	POT OR	Yes	Yes	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	POT CS	No	No	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	SOD	139	137	.	.	.	.	.	135	140	.	.
01-1002	Standard of Care	TPROT	5.2	5.6	.	.	.	.	.	5.6	5.9	.	.
01-1002	Standard of Care	TPROT OR	Yes	Yes	.	.	.	.	.	Yes	Yes	.	.
01-1002	Standard of Care	TPROT CS	No	No	.	.	.	.	.	No	No	.	.

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked red.

Subject	Group	Variable abbrev.	Visit											
			1	8	11	15	18	22	29	30	31	33		
01-1002	Standard of Care	UREA	.	0.3	.	.	.	.	.	.	.	.	.	.
01-1003	Tafoxiparin+Standard of Care	ALT	26	34	.	.	.	.	.	.	44	86	.	.
01-1003	Tafoxiparin+Standard of Care	ALT OR	.	.	.	.	.	.	.	.	Yes	Yes	.	.
01-1003	Tafoxiparin+Standard of Care	ALT CS	.	.	.	.	.	.	.	.	No	No	.	.
01-1003	Tafoxiparin+Standard of Care	AST	23	27	.	.	.	.	.	.	37	25	.	.
01-1003	Tafoxiparin+Standard of Care	AST OR	.	.	.	.	.	.	.	.	Yes	.	.	.
01-1003	Tafoxiparin+Standard of Care	AST CS	.	.	.	.	.	.	.	.	No	.	.	.
01-1003	Tafoxiparin+Standard of Care	CALC	7.9	8.1	.	.	.	.	.	.	8	8.7	.	.
01-1003	Tafoxiparin+Standard of Care	CALC OR	Yes	Yes	.	.	.	.	.	.	Yes	.	.	.
01-1003	Tafoxiparin+Standard of Care	CALC CS	No	No	.	.	.	.	.	.	No	.	.	.
01-1003	Tafoxiparin+Standard of Care	CREA	0.6	0.66	.	.	.	.	.	.	0.8	0.57	.	.
01-1003	Tafoxiparin+Standard of Care	POT	4.8	4.2	.	.	.	.	.	.	4.8	4.2	.	.
01-1003	Tafoxiparin+Standard of Care	SOD	133	135	.	.	.	.	.	.	137	142	.	.
01-1003	Tafoxiparin+Standard of Care	SOD OR	Yes	.	.	.	.	.	.	.	.	.	.	.
01-1003	Tafoxiparin+Standard of Care	SOD CS	No	.	.	.	.	.	.	.	.	.	.	.
01-1003	Tafoxiparin+Standard of Care	TPROT	4.7	.	.	.	.	.	.	.	4	4.9	.	.
01-1003	Tafoxiparin+Standard of Care	TPROT OR	Yes	.	.	.	.	.	.	.	Yes	.	.	.
01-1003	Tafoxiparin+Standard of Care	TPROT CS	No	.	.	.	.	.	.	.	No	.	.	.
01-1004	Tafoxiparin+Standard of Care	ALT	46	.	.	.	.	.	.	.	79	32	.	.
01-1004	Tafoxiparin+Standard of Care	ALT OR	Yes	.	.	.	.	.	.	.	Yes	.	.	.
01-1004	Tafoxiparin+Standard of Care	ALT CS	No	.	.	.	.	.	.	.	No	.	.	.
01-1004	Tafoxiparin+Standard of Care	AST	73	.	.	.	.	.	.	.	55	19	.	.
01-1004	Tafoxiparin+Standard of Care	AST OR	Yes	.	.	.	.	.	.	.	Yes	.	.	.
01-1004	Tafoxiparin+Standard of Care	AST CS	No	.	.	.	.	.	.	.	No	.	.	.
01-1004	Tafoxiparin+Standard of Care	BILIT	0.15	.	.	.	.	.	.	.	.	.	.	.
01-1004	Tafoxiparin+Standard of Care	CALC	7.6	.	.	.	.	.	.	.	6.7	8.1	.	.
01-1004	Tafoxiparin+Standard of Care	CALC OR	.	.	.	.	.	.	.	.	Yes	Yes	.	.
01-1004	Tafoxiparin+Standard of Care	CALC CS	.	.	.	.	.	.	.	.	No	No	.	.
01-1004	Tafoxiparin+Standard of Care	CREA	0.52	.	.	.	.	.	.	.	0.48	0.44	.	.
01-1004	Tafoxiparin+Standard of Care	CREA OR	.	.	.	.	.	.	.	.	Yes	Yes	.	.
01-1004	Tafoxiparin+Standard of Care	CREA CS	.	.	.	.	.	.	.	.	No	No	.	.
01-1004	Tafoxiparin+Standard of Care	POT	4.9	.	.	.	.	.	.	.	4.4	3.8	.	.
01-1004	Tafoxiparin+Standard of Care	SOD	135	.	.	.	.	.	.	.	127	142	.	.
01-1004	Tafoxiparin+Standard of Care	SOD OR	.	.	.	.	.	.	.	.	Yes	.	.	.
01-1004	Tafoxiparin+Standard of Care	SOD CS	.	.	.	.	.	.	.	.	No	.	.	.
01-1004	Tafoxiparin+Standard of Care	TPROT	.	.	.	.	.	.	.	.	3.4	4.3	.	.

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked red.

Subject	Group	Variable abbrev.	Visit									
			1	8	11	15	18	22	29	30	31	33
01-1004	Tafoxiparin+Standard of Care	TPROT OR	.	.	.	.	.	.	.	Yes	Yes	.
01-1004	Tafoxiparin+Standard of Care	TPROT CS	.	.	.	.	.	.	.	No	No	.
01-1005	Not Randomised	ALT	19	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	AST	20	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	CREA	0.77	.	.	.	.	.	.	.	.	.
02-1001	Tafoxiparin+Standard of Care	ALB	2.9	.	.	.	.	.	.	2.6	3	.
02-1001	Tafoxiparin+Standard of Care	ALB OR	Yes	.	.	.	.	.	.	Yes	Yes	.
02-1001	Tafoxiparin+Standard of Care	ALB CS	No	.	.	.	.	.	.	Yes	No	.
02-1001	Tafoxiparin+Standard of Care	ALP	.	.	.	.	.	.	.	.	.	114
02-1001	Tafoxiparin+Standard of Care	ALT	17	.	.	.	.	.	.	20	33	103
02-1001	Tafoxiparin+Standard of Care	ALT OR	.	.	.	.	.	.	.	.	Yes	Yes
02-1001	Tafoxiparin+Standard of Care	ALT CS	.	.	.	.	.	.	.	.	No	Yes
02-1001	Tafoxiparin+Standard of Care	AST	.	.	.	.	.	.	.	.	.	45
02-1001	Tafoxiparin+Standard of Care	AST OR	.	.	.	.	.	.	.	.	.	Yes
02-1001	Tafoxiparin+Standard of Care	AST CS	.	.	.	.	.	.	.	.	.	No
02-1001	Tafoxiparin+Standard of Care	BILIC	.	.	.	.	.	.	.	.	.	0.3
02-1001	Tafoxiparin+Standard of Care	BILIT	0.3	.	.	.	.	.	.	0.45	0.71	0.3
02-1001	Tafoxiparin+Standard of Care	CALC	.	.	.	.	.	.	.	.	.	9.4
02-1001	Tafoxiparin+Standard of Care	CREA	0.65	.	.	.	.	.	.	1.06	0.77	0.61
02-1001	Tafoxiparin+Standard of Care	POT	4.2	.	.	.	.	.	.	6	3.8	4
02-1001	Tafoxiparin+Standard of Care	POT OR	.	.	.	.	.	.	.	Yes	.	.
02-1001	Tafoxiparin+Standard of Care	POT CS	.	.	.	.	.	.	.	No	.	.
02-1001	Tafoxiparin+Standard of Care	SOD	133	.	.	.	.	.	.	129	132	139
02-1001	Tafoxiparin+Standard of Care	SOD OR	Yes	.	.	.	.	.	.	Yes	.	.
02-1001	Tafoxiparin+Standard of Care	SOD CS	No	.	.	.	.	.	.	No	.	.
02-1001	Tafoxiparin+Standard of Care	TPROT	.	.	.	.	.	.	.	.	.	7.4
02-1001	Tafoxiparin+Standard of Care	UREA	25	.	.	.	.	.	.	27	16	24
02-1002	Tafoxiparin+Standard of Care	ALB	3.4	3.2	.	.	.	.	.	1.9	3	4.3
02-1002	Tafoxiparin+Standard of Care	ALB OR	Yes	Yes	.	.	.	.	.	Yes	Yes	.
02-1002	Tafoxiparin+Standard of Care	ALB CS	No	No	.	.	.	.	.	Yes	No	.
02-1002	Tafoxiparin+Standard of Care	ALP	.	106	.	.	.	.	.	.	69	48
02-1002	Tafoxiparin+Standard of Care	ALT	12	17	.	.	.	.	.	11	17	16
02-1002	Tafoxiparin+Standard of Care	AST	.	28	.	.	.	.	.	.	17	21
02-1002	Tafoxiparin+Standard of Care	BILIC	.	0.4	.	.	.	.	.	.	0.3	0.3
02-1002	Tafoxiparin+Standard of Care	BILIC OR	.	Yes	.	.	.	.	.	.	.	.
02-1002	Tafoxiparin+Standard of Care	BILIC CS	.	No	.	.	.	.	.	.	.	.

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked **red**.

Subject	Group	Variable abbrev.	Visit									
			1	8	11	15	18	22	29	30	31	33
02-1002	Tafoxiparin+Standard of Care	BILIT	0.3	0.74	.	.	.	.	.	0.3	0.3	0.3
02-1002	Tafoxiparin+Standard of Care	CALC	.	6.7	.	.	.	.	.	.	8.3	9.5
02-1002	Tafoxiparin+Standard of Care	CALC OR	.	Yes	.	.	.	.	.	.	Yes	.
02-1002	Tafoxiparin+Standard of Care	CALC CS	.	No	.	.	.	.	.	.	No	.
02-1002	Tafoxiparin+Standard of Care	CREA	0.78	0.94	.	.	.	.	.	1.18	0.75	1.07
02-1002	Tafoxiparin+Standard of Care	POT	4.1	4.4	.	.	.	.	.	4.2	3.5	3.9
02-1002	Tafoxiparin+Standard of Care	SOD	131	130	.	.	.	.	.	128	132	140
02-1002	Tafoxiparin+Standard of Care	SOD OR	Yes	Yes	.	.	.	.	.	Yes	Yes	.
02-1002	Tafoxiparin+Standard of Care	SOD CS	No	No	.	.	.	.	.	No	No	.
02-1002	Tafoxiparin+Standard of Care	TPROT	.	.	.	.	.	.	.	.	.	7
02-1002	Tafoxiparin+Standard of Care	UREA	26	41	.	.	.	.	.	.	29	39
02-1003	Tafoxiparin+Standard of Care	ALB	3.2	.	.	.	.	.	.	3	.	.
02-1003	Tafoxiparin+Standard of Care	ALB OR	Yes	.	.	.	.	.	.	Yes	.	.
02-1003	Tafoxiparin+Standard of Care	ALB CS	No	.	.	.	.	.	.	No	.	.
02-1003	Tafoxiparin+Standard of Care	ALP	.	.	.	.	.	.	.	.	.	82
02-1003	Tafoxiparin+Standard of Care	ALT	11	.	.	.	.	.	.	11	.	26
02-1003	Tafoxiparin+Standard of Care	AST	.	.	.	.	.	.	.	.	.	14
02-1003	Tafoxiparin+Standard of Care	BILIC	.	.	.	.	.	.	.	.	.	0.3
02-1003	Tafoxiparin+Standard of Care	BILIT	0.3	.	.	.	.	.	.	0.3	.	0.32
02-1003	Tafoxiparin+Standard of Care	CALC	.	.	.	.	.	.	.	.	.	9.4
02-1003	Tafoxiparin+Standard of Care	CREA	0.6	.	.	.	.	.	.	0.58	.	0.72
02-1003	Tafoxiparin+Standard of Care	POT	3.7	.	.	.	.	.	.	3.9	.	3.7
02-1003	Tafoxiparin+Standard of Care	SOD	136	.	.	.	.	.	.	136	.	144
02-1003	Tafoxiparin+Standard of Care	TPROT	.	.	.	.	.	.	.	.	.	8
02-1003	Tafoxiparin+Standard of Care	UREA	25	.	.	.	.	.	.	19	.	35
02-1004	Tafoxiparin+Standard of Care	ALB	3	3.3	3	.	.	.	.	2.5	2.5	4.4
02-1004	Tafoxiparin+Standard of Care	ALB OR	Yes	Yes	Yes	.	.	.	.	Yes	.	.
02-1004	Tafoxiparin+Standard of Care	ALB CS	No	No	No	.	.	.	.	<b>Yes</b>	.	.
02-1004	Tafoxiparin+Standard of Care	ALP	.	84	.	.	.	.	.	.	.	76
02-1004	Tafoxiparin+Standard of Care	ALT	15	13	17	.	.	.	.	14	19	230
02-1004	Tafoxiparin+Standard of Care	ALT OR	.	.	.	.	.	.	.	.	.	Yes
02-1004	Tafoxiparin+Standard of Care	ALT CS	.	.	.	.	.	.	.	.	.	Yes
02-1004	Tafoxiparin+Standard of Care	AST	.	16	.	.	.	.	.	.	.	153
02-1004	Tafoxiparin+Standard of Care	AST OR	.	.	.	.	.	.	.	.	.	Yes
02-1004	Tafoxiparin+Standard of Care	AST CS	.	.	.	.	.	.	.	.	.	<b>Yes</b>
02-1004	Tafoxiparin+Standard of Care	BILIC	.	0.3	.	.	.	.	.	.	.	0.3

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked red.

Subject	Group	Variable abbrev.	Visit									
			1	8	11	15	18	22	29	30	31	33
02-1004	Tafoxiparin+Standard of Care	BILIT	0.3	0.3	0.44	.	.	.	.	0.49	0.42	0.44
02-1004	Tafoxiparin+Standard of Care	CALC	.	8.6	.	.	.	.	.	.	.	9.2
02-1004	Tafoxiparin+Standard of Care	CREA	0.53	0.54	0.52	.	.	.	.	0.62	0.5	0.62
02-1004	Tafoxiparin+Standard of Care	POT	4.1	5.2	4.1	.	.	.	.	4.6	3.4	4
02-1004	Tafoxiparin+Standard of Care	POT OR	.	.	.	.	.	.	.	.	Yes	.
02-1004	Tafoxiparin+Standard of Care	POT CS	.	.	.	.	.	.	.	.	No	.
02-1004	Tafoxiparin+Standard of Care	SOD	135	135	136	.	.	.	.	134	136	140
02-1004	Tafoxiparin+Standard of Care	SOD OR	Yes	Yes	.	.	.	.	.	Yes	.	.
02-1004	Tafoxiparin+Standard of Care	SOD CS	No	No	.	.	.	.	.	No	.	.
02-1004	Tafoxiparin+Standard of Care	TPROT	.	6.8	.	.	.	.	.	.	.	8.3
02-1004	Tafoxiparin+Standard of Care	TPROT OR	.	.	.	.	.	.	.	.	.	Yes
02-1004	Tafoxiparin+Standard of Care	TPROT CS	.	.	.	.	.	.	.	.	.	No
02-1004	Tafoxiparin+Standard of Care	UREA	19	21	32	.	.	.	.	26	18	26
02-1005	Tafoxiparin+Standard of Care	ALB	3.5	3.3	3.7	3.9	3.9	3.8	3.3	2.7	2.9	4.1
02-1005	Tafoxiparin+Standard of Care	ALB OR	.	Yes	.	.	.	.	Yes	Yes	Yes	.
02-1005	Tafoxiparin+Standard of Care	ALB CS	.	No	.	.	.	.	No	No	No	.
02-1005	Tafoxiparin+Standard of Care	ALP	95	84	112	99	108	97	101	77	63	82
02-1005	Tafoxiparin+Standard of Care	ALT	9	9	11	14	15	14	11	12	19	58
02-1005	Tafoxiparin+Standard of Care	ALT OR	.	.	.	.	.	.	.	.	.	Yes
02-1005	Tafoxiparin+Standard of Care	ALT CS	.	.	.	.	.	.	.	.	.	No
02-1005	Tafoxiparin+Standard of Care	AST	18	17	22	12	17	12	16	15	17	37
02-1005	Tafoxiparin+Standard of Care	AST OR	.	.	.	.	.	.	.	.	.	Yes
02-1005	Tafoxiparin+Standard of Care	AST CS	.	.	.	.	.	.	.	.	.	No
02-1005	Tafoxiparin+Standard of Care	BILIC	0.3	0.3	0.3	0.3	.	0.3	0.3	0.3	0.3	0.3
02-1005	Tafoxiparin+Standard of Care	BILIT	0.32	0.38	0.3	0.3	0.3	0.33	0.31	0.59	0.3	0.45
02-1005	Tafoxiparin+Standard of Care	CALC	8.9	8.9	9.5	9.3	9.2	9.7	8.9	8.2	8.3	8.9
02-1005	Tafoxiparin+Standard of Care	CALC OR	.	.	.	.	.	.	.	Yes	Yes	.
02-1005	Tafoxiparin+Standard of Care	CALC CS	.	.	.	.	.	.	.	No	No	.
02-1005	Tafoxiparin+Standard of Care	CREA	0.42	0.45	0.39	0.48	0.47	0.52	0.49	0.57	0.49	0.5
02-1005	Tafoxiparin+Standard of Care	CREA OR	Yes	Yes	Yes	Yes	Yes	.	Yes	.	Yes	.
02-1005	Tafoxiparin+Standard of Care	CREA CS	No	No	No	No	No	.	No	.	No	.
02-1005	Tafoxiparin+Standard of Care	POT	3.8	4.4	6.4	4.2	4.6	4.4	4	4	3.6	4.2
02-1005	Tafoxiparin+Standard of Care	POT OR	.	.	Yes	.	.	.	.	.	.	.
02-1005	Tafoxiparin+Standard of Care	POT CS	.	.	Yes	.	.	.	.	.	.	.
02-1005	Tafoxiparin+Standard of Care	SOD	136	135	135	135	135	133	135	134	136	135
02-1005	Tafoxiparin+Standard of Care	SOD OR	.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	.	Yes

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked red.

Subject	Group	Variable abbrev.	Visit										
			1	8	11	15	18	22	29	30	31	33	
02-1005	Tafoxiparin+Standard of Care	SOD CS	.	No	No	No	No	No	No	No	No	.	No
02-1005	Tafoxiparin+Standard of Care	TPROT	6.2	.	7	.	6.8	6.9	6.1	5.2	5.2	7.1	
02-1005	Tafoxiparin+Standard of Care	TPROT OR	.	.	.	.	.	.	.	Yes	Yes	.	
02-1005	Tafoxiparin+Standard of Care	TPROT CS	.	.	.	.	.	.	.	Yes	Yes	.	
02-1005	Tafoxiparin+Standard of Care	UREA	11	18	18	17	17	18	22	30	18	20	
02-1005	Tafoxiparin+Standard of Care	UREA OR	Yes	.	.	.	.	.	.	.	.	.	
02-1005	Tafoxiparin+Standard of Care	UREA CS	No	.	.	.	.	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	ALB	3.7	.	.	3.3	3.4	.	3.36	2.9	.	4.4	
02-1006	Tafoxiparin+Standard of Care	ALB OR	.	.	.	Yes	Yes	.	.	Yes	.	.	
02-1006	Tafoxiparin+Standard of Care	ALB CS	.	.	.	No	No	.	.	No	.	.	
02-1006	Tafoxiparin+Standard of Care	ALP	108	.	.	109	127	111	132	.	.	115	
02-1006	Tafoxiparin+Standard of Care	ALP OR	.	.	.	.	Yes	.	Yes	.	.	.	
02-1006	Tafoxiparin+Standard of Care	ALP CS	.	.	.	.	No	.	No	.	.	.	
02-1006	Tafoxiparin+Standard of Care	ALT	18	.	.	16	21	15	17	30	.	25	
02-1006	Tafoxiparin+Standard of Care	AST	23	.	.	19	16	19	20	.	.	20	
02-1006	Tafoxiparin+Standard of Care	AST OR	.	.	.	.	.	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	BILIC	0.3	.	.	0.3	0.3	0.3	0.3	0.3	.	0.1	
02-1006	Tafoxiparin+Standard of Care	BILIT	0.3	.	.	0.3	0.3	0.3	0.36	0.3	.	0.34	
02-1006	Tafoxiparin+Standard of Care	CALC	9.4	.	.	8.8	8.9	8.7	9.2	.	.	9.6	
02-1006	Tafoxiparin+Standard of Care	CREA	0.45	.	.	0.52	0.6	0.56	0.59	0.54	.	.	
02-1006	Tafoxiparin+Standard of Care	CREA OR	Yes	.	.	.	.	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	CREA CS	No	.	.	.	.	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	POT	3.6	.	.	3.6	4	3.8	3.5	3.7	.	4.1	
02-1006	Tafoxiparin+Standard of Care	SOD	137	.	.	138	135	138	136	135	.	138	
02-1006	Tafoxiparin+Standard of Care	SOD OR	.	.	.	.	Yes	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	SOD CS	.	.	.	.	No	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	TPROT	6.2	.	.	5.6	6	6	6.3	.	.	.	
02-1006	Tafoxiparin+Standard of Care	TPROT OR	.	.	.	Yes	.	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	TPROT CS	.	.	.	No	.	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	UREA	20	.	.	17	13	15	16	12	.	33	
02-1006	Tafoxiparin+Standard of Care	UREA OR	.	.	.	.	Yes	.	.	.	.	.	
02-1006	Tafoxiparin+Standard of Care	UREA CS	.	.	.	.	No	.	.	.	.	.	
02-1007	Not Randomised	ALB	2.6	.	.	.	.	.	.	.	.	.	
02-1007	Not Randomised	ALB OR	Yes	.	.	.	.	.	.	.	.	.	
02-1007	Not Randomised	ALB CS	No	.	.	.	.	.	.	.	.	.	
02-1007	Not Randomised	ALP	231	.	.	.	.	.	.	.	.	.	

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked red.

Subject	Group	Variable abbrev.	Visit									
			1	8	11	15	18	22	29	30	31	33
02-1007	Not Randomised	ALP OR	Yes	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	ALP CS	No	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	ALT	10	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	AST	20	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	BILIC	0.3	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	BILIT	0.3	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	CALC	8.6	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	CREA	0.82	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	POT	4.9	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	SOD	131	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	SOD OR	Yes	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	SOD CS	No	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	TPROT	5.4	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	TPROT OR	Yes	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	TPROT CS	No	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	UREA	65	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	UREA OR	Yes	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	UREA CS	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	ALB	2.9	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	ALB OR	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	ALB CS	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	ALP	74	.	.	.	.	.	.	.	.	74
02-1008	Standard of Care	ALT	31	.	.	.	.	.	.	.	.	25
02-1008	Standard of Care	AST	23	.	.	.	.	.	.	.	.	25
02-1008	Standard of Care	BILIC	0.3	.	.	.	.	.	.	.	.	0.1
02-1008	Standard of Care	BILIT	0.3	.	.	.	.	.	.	.	.	0.4
02-1008	Standard of Care	CALC	7.5	.	.	.	.	.	.	.	.	9.4
02-1008	Standard of Care	CALC OR	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	CALC CS	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	CREA	0.59	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	POT	3.3	.	.	.	.	.	.	.	.	3.8
02-1008	Standard of Care	SOD	134	.	.	.	.	.	.	.	.	139
02-1008	Standard of Care	TPROT	5.2	.	.	.	.	.	.	.	.	7.7
02-1008	Standard of Care	TPROT OR	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	TPROT CS	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	UREA	26	.	.	.	.	.	.	.	.	21

Table 1 Clinical chemistry by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table. Data outside the reference range and assessed as clinically significant are marked **red**.

Subject	Group	Variable abbrev.	Visit									
			1	8	11	15	18	22	29	30	31	33
02-1010	Tafoxiparin+Standard of Care	ALB	2.8	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	ALB OR	Yes	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	ALB CS	No	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	ALT	21	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	BILIT	0.4	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	CREA	0.37	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	CREA OR	Yes	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	CREA CS	No	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	POT	4.2	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	SOD	136	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	UREA	20	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	UREA OR	Yes	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	UREA CS	No	.	.	.	.	.	.	.	.	.

Table 9 below show which hematology data were collected. In the subjects who received at least one dose of tafoxiparin, several hundred clinical chemistry tests were performed. Ten of these were assessed as Clinically Significant outside the reference range, but none were of major significance. Data outside the reference range assessed as clinically significant are highlighted in **red** in table 10.

Table 9 Haematology variable abbreviations. Source: PPL20_BLH hematology MÅ01. Sheet: Variable abbreviations MÅ01.	
Variable	Variable Abbreviation
White blood cell count	WBCC
Platelet Count	PLAT
Hematocrit	HEMA
Hemoglobin	HB
Red blood cell count	RBCC
fL	MCV_fL
pg	MCH_pg

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”.**  
**The variable abbreviations are explained in Table .**  
**Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
01-1001	Not Randomised	HB	12.2	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	HEMA	35.8	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	MCH	29.8	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	MCV	87.3	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	PLAT	256	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	RBCC	4.1	.	.	.	.	.	.	.	.	.	.
01-1001	Not Randomised	WBCC	16.6	.	.	.	.	.	.	.	.	.	.
01-1002	Standard of Care	HB	10.6	10.7	10.7	.	.	.	.	.	10.9	7.8	12.9
01-1002	Standard of Care	HB OR	.	Yes	Yes	.	.	.	.	.	Yes	Yes	Yes
01-1002	Standard of Care	HB CS	.	No	No	.	.	.	.	.	No	No	.
01-1002	Standard of Care	HEMA	32.2	32.7	33.5	.	.	.	.	.	33.9	24.6	39.5
01-1002	Standard of Care	HEMA OR	Yes	Yes	Yes	.	.	.	.	.	Yes	Yes	Yes
01-1002	Standard of Care	HEMA CS	No	No	No	.	.	.	.	.	No	No	.
01-1002	Standard of Care	MCH	27.5	27.6	27.2	.	.	.	.	.	27.6	28.3	28.2
01-1002	Standard of Care	MCH OR	.	.	.	.	.	.	.	.	.	.	Yes
01-1002	Standard of Care	MCV	83.4	84.5	85	.	.	.	.	.	85.8	89.1	86.2
01-1002	Standard of Care	MCV OR	.	.	.	.	.	.	.	.	.	.	Yes
01-1002	Standard of Care	PLAT	172	159	182	.	.	.	.	.	206	402	241
01-1002	Standard of Care	PLAT OR	.	.	.	.	.	.	.	.	.	.	Yes
01-1002	Standard of Care	RBCC	3.8	3.8	3.94	.	.	.	.	.	3.95	2.76	4.58
01-1002	Standard of Care	RBCC OR	Yes	Yes	Yes	.	.	.	.	.	Yes	Yes	Yes
01-1002	Standard of Care	RBCC CS	No	No	No	.	.	.	.	.	No	No	.
01-1002	Standard of Care	WBCC	9.7	9.1	8.3	.	.	.	.	.	13.6	10.3	4.96
01-1002	Standard of Care	WBCC OR	.	.	.	.	.	.	.	.	Yes	Yes	Yes
01-1002	Standard of Care	WBCC CS	.	.	.	.	.	.	.	.	No	No	.
01-1003	Tafoxiparin+Standard of Care	HB	10.4	11.3	11.4	.	.	.	.	.	10.7	9.4	.
01-1003	Tafoxiparin+Standard of Care	HB OR	Yes	Yes	Yes	.	.	.	.	.	Yes	Yes	.
01-1003	Tafoxiparin+Standard of Care	HB CS	No	No	No	.	.	.	.	.	No	No	.
01-1003	Tafoxiparin+Standard of Care	HEMA	32	36	35.3	.	.	.	.	.	32	93.5	.
01-1003	Tafoxiparin+Standard of Care	HEMA OR	.	.	Yes	.	.	.	.	.	Yes	.	.
01-1003	Tafoxiparin+Standard of Care	HEMA CS	.	.	No	.	.	.	.	.	No	.	.
01-1003	Tafoxiparin+Standard of Care	MCH	29.4	28.8	29.7	.	.	.	.	.	29.9	30.5	.
01-1003	Tafoxiparin+Standard of Care	MCV	90.4	91.6	91.9	.	.	.	.	.	89.4	93.5	.
01-1003	Tafoxiparin+Standard of Care	PLAT	225	201	158	.	.	.	.	.	134	160	.
01-1003	Tafoxiparin+Standard of Care	RBCC	3.54	3.93	3.84	.	.	.	.	.	3.58	3.08	.
01-1003	Tafoxiparin+Standard of Care	RBCC OR	Yes	Yes	Yes	.	.	.	.	.	Yes	Yes	.

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”.  
The variable abbreviations are explained in Table .  
Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
01-1003	Tafoxiparin+Standard of Care	RBCC CS	No	No	No	.	.	.	.	.	No	No	.
01-1003	Tafoxiparin+Standard of Care	WBCC	15.6	6.1	8.46	.	.	.	.	.	10.1	7.21	.
01-1003	Tafoxiparin+Standard of Care	WBCC OR	Yes	.	.	.	.	.	.	.	Yes	.	.
01-1003	Tafoxiparin+Standard of Care	WBCC CS	No	.	.	.	.	.	.	.	No	.	.
01-1004	Tafoxiparin+Standard of Care	HB	10.6	10.1	.	.	.	.	.	.	9.2	8	.
01-1004	Tafoxiparin+Standard of Care	HB OR	Yes	Yes	.	.	.	.	.	.	Yes	Yes	.
01-1004	Tafoxiparin+Standard of Care	HB CS	No	No	.	.	.	.	.	.	Yes	Yes	.
01-1004	Tafoxiparin+Standard of Care	HEMA	31.4	28.4	.	.	.	.	.	.	25.6	24.9	.
01-1004	Tafoxiparin+Standard of Care	HEMA OR	Yes	Yes	.	.	.	.	.	.	Yes	Yes	.
01-1004	Tafoxiparin+Standard of Care	HEMA CS	No	No	.	.	.	.	.	.	Yes	No	.
01-1004	Tafoxiparin+Standard of Care	MCH	30.9	30.3	.	.	.	.	.	.	31.2	31	.
01-1004	Tafoxiparin+Standard of Care	MCV	91.5	85.3	.	.	.	.	.	.	86.8	96.5	.
01-1004	Tafoxiparin+Standard of Care	MCV OR	.	.	.	.	.	.	.	.	.	Yes	.
01-1004	Tafoxiparin+Standard of Care	MCV CS	.	.	.	.	.	.	.	.	.	No	.
01-1004	Tafoxiparin+Standard of Care	PLAT	177	159	.	.	.	.	.	.	171	274	.
01-1004	Tafoxiparin+Standard of Care	RBCC	3.43	3.33	.	.	.	.	.	.	2.95	2.58	.
01-1004	Tafoxiparin+Standard of Care	RBCC OR	Yes	.	.	.	.	.	.	.	Yes	Yes	.
01-1004	Tafoxiparin+Standard of Care	RBCC CS	No	.	.	.	.	.	.	.	Yes	No	.
01-1004	Tafoxiparin+Standard of Care	WBCC	7.55	5.87	.	.	.	.	.	.	10.8	7.7	.
01-1004	Tafoxiparin+Standard of Care	WBCC OR	.	.	.	.	.	.	.	.	Yes	.	.
01-1004	Tafoxiparin+Standard of Care	WBCC CS	.	.	.	.	.	.	.	.	No	.	.
01-1005	Not Randomised	HB	12.2	.	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	HEMA	36.1	.	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	MCH	31.5	.	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	MCV	93.3	.	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	PLAT	135	.	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	RBCC	3.87	.	.	.	.	.	.	.	.	.	.
01-1005	Not Randomised	WBCC	6.49	.	.	.	.	.	.	.	.	.	.
02-1001	Tafoxiparin+Standard of Care	HB	12.4	.	.	.	.	.	.	.	11.4	7.1	14.4
02-1001	Tafoxiparin+Standard of Care	HB OR	.	.	.	.	.	.	.	.	Yes	Yes	.
02-1001	Tafoxiparin+Standard of Care	HB CS	.	.	.	.	.	.	.	.	No	Yes	.
02-1001	Tafoxiparin+Standard of Care	HEMA	36.7	.	.	.	.	.	.	.	33	21	42.5
02-1001	Tafoxiparin+Standard of Care	HEMA OR	.	.	.	.	.	.	.	.	Yes	Yes	.
02-1001	Tafoxiparin+Standard of Care	HEMA CS	.	.	.	.	.	.	.	.	No	No	.
02-1001	Tafoxiparin+Standard of Care	MCH	27	.	.	.	.	.	.	.	27.5	27.4	28.9
02-1001	Tafoxiparin+Standard of Care	MCV	79.8	.	.	.	.	.	.	.	79.5	80.5	85.1

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table . Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
02-1001	Tafoxiparin+Standard of Care	MCV OR	.	.	.	.	.	.	.	.	Yes	.	.
02-1001	Tafoxiparin+Standard of Care	MCV CS	.	.	.	.	.	.	.	.	No	.	.
02-1001	Tafoxiparin+Standard of Care	PLAT	190	.	.	.	.	.	.	.	173	199	263
02-1001	Tafoxiparin+Standard of Care	RBCC	4.6	.	.	.	.	.	.	.	4.15	2.61	4.99
02-1001	Tafoxiparin+Standard of Care	RBCC OR	.	.	.	.	.	.	.	.	.	Yes	.
02-1001	Tafoxiparin+Standard of Care	RBCC CS	.	.	.	.	.	.	.	.	.	No	.
02-1001	Tafoxiparin+Standard of Care	RETI	.	.	.	.	.	.	.	.	.	.	1.8
02-1001	Tafoxiparin+Standard of Care	WBCC	7.49	.	.	.	.	.	.	.	14.75	8.34	7.51
02-1001	Tafoxiparin+Standard of Care	WBCC OR	.	.	.	.	.	.	.	.	Yes	.	.
02-1001	Tafoxiparin+Standard of Care	WBCC CS	.	.	.	.	.	.	.	.	No	.	.
02-1002	Tafoxiparin+Standard of Care	HB	10	10.7	10	.	.	.	.	.	5.3	9.9	11.4
02-1002	Tafoxiparin+Standard of Care	HB OR	Yes	Yes	Yes	.	.	.	.	.	Yes	Yes	Yes
02-1002	Tafoxiparin+Standard of Care	HB CS	No	No	No	.	.	.	.	.	Yes	No	No
02-1002	Tafoxiparin+Standard of Care	HEMA	30.5	31.6	30.3	.	.	.	.	.	15.5	28.2	33.9
02-1002	Tafoxiparin+Standard of Care	HEMA OR	.	Yes	Yes	.	.	.	.	.	Yes	Yes	Yes
02-1002	Tafoxiparin+Standard of Care	HEMA CS	.	No	No	.	.	.	.	.	Yes	No	No
02-1002	Tafoxiparin+Standard of Care	MCH	25.1	26	25.7	.	.	.	.	.	26.2	28.7	26.8
02-1002	Tafoxiparin+Standard of Care	MCV	77	77	77.8	.	.	.	.	.	76.9	82	80
02-1002	Tafoxiparin+Standard of Care	MCV OR	Yes	Yes	Yes	.	.	.	.	.	Yes	.	.
02-1002	Tafoxiparin+Standard of Care	MCV CS	No	No	No	.	.	.	.	.	No	.	.
02-1002	Tafoxiparin+Standard of Care	PLAT	202	110	104	.	.	.	.	.	117	207	380
02-1002	Tafoxiparin+Standard of Care	PLAT OR	.	Yes	Yes	.	.	.	.	.	Yes	.	.
02-1002	Tafoxiparin+Standard of Care	PLAT CS	.	Yes	No	.	.	.	.	.	Yes	.	.
02-1002	Tafoxiparin+Standard of Care	RBCC	3.97	4.1	3.89	.	.	.	.	.	2.02	3.44	4.24
02-1002	Tafoxiparin+Standard of Care	RBCC OR	Yes	.	Yes	.	.	.	.	.	Yes	Yes	.
02-1002	Tafoxiparin+Standard of Care	RBCC CS	.	.	No	.	.	.	.	.	Yes	No	.
02-1002	Tafoxiparin+Standard of Care	RETI	.	.	4.4	.	.	.	.	.	.	8.4	1.6
02-1002	Tafoxiparin+Standard of Care	RETI OR	.	.	Yes	.	.	.	.	.	.	Yes	.
02-1002	Tafoxiparin+Standard of Care	RETI CS	.	.	Yes	.	.	.	.	.	.	No	.
02-1002	Tafoxiparin+Standard of Care	WBCC	15.47	10.42	13.49	.	.	.	.	.	18.12	11.48	5.78
02-1002	Tafoxiparin+Standard of Care	WBCC OR	Yes	.	Yes	.	.	.	.	.	Yes	Yes	.
02-1002	Tafoxiparin+Standard of Care	WBCC CS	No	.	No	.	.	.	.	.	No	No	.
02-1003	Tafoxiparin+Standard of Care	HB	13.7	.	.	.	.	.	.	.	11.7	.	13.6
02-1003	Tafoxiparin+Standard of Care	HB OR	.	.	.	.	.	.	.	.	Yes	.	.
02-1003	Tafoxiparin+Standard of Care	HB CS	.	.	.	.	.	.	.	.	No	.	.
02-1003	Tafoxiparin+Standard of Care	HEMA	39.3	.	.	.	.	.	.	.	34.6	.	42.6

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table . Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
02-1003	Tafoxiparin+Standard of Care	HEMA OR	.	.	.	.	.	.	.	.	Yes	.	.
02-1003	Tafoxiparin+Standard of Care	HEMA CS	.	.	.	.	.	.	.	.	No	.	.
02-1003	Tafoxiparin+Standard of Care	MCH	28.1	.	.	.	.	.	.	.	28.1	.	25.9
02-1003	Tafoxiparin+Standard of Care	MCH OR	.	.	.	.	.	.	.	.	.	.	Yes
02-1003	Tafoxiparin+Standard of Care	MCH CS	.	.	.	.	.	.	.	.	.	.	No
02-1003	Tafoxiparin+Standard of Care	MCV	80.9	.	.	.	.	.	.	.	82.8	.	81
02-1003	Tafoxiparin+Standard of Care	PLAT	173	.	.	.	.	.	.	.	166	.	287
02-1003	Tafoxiparin+Standard of Care	RBCC	4.86	.	.	.	.	.	.	.	4.17	.	5.26
02-1003	Tafoxiparin+Standard of Care	RBCC OR	.	.	.	.	.	.	.	.	.	.	Yes
02-1003	Tafoxiparin+Standard of Care	RBCC CS	.	.	.	.	.	.	.	.	.	.	No
02-1003	Tafoxiparin+Standard of Care	RETI	.	.	.	.	.	.	.	.	.	.	1.9
02-1003	Tafoxiparin+Standard of Care	WBCC	11.17	.	.	.	.	.	.	.	11.53	.	9.01
02-1003	Tafoxiparin+Standard of Care	WBCC OR	Yes	.	.	.	.	.	.	.	Yes	.	.
02-1003	Tafoxiparin+Standard of Care	WBCC CS	No	.	.	.	.	.	.	.	No	.	.
02-1004	Tafoxiparin+Standard of Care	HB	12.1	12.1	12.5	11.6	.	.	.	.	11.2	8.4	11.9
02-1004	Tafoxiparin+Standard of Care	HB OR	.	.	.	Yes	.	.	.	.	Yes	Yes	Yes
02-1004	Tafoxiparin+Standard of Care	HB CS	.	.	.	No	.	.	.	.	No	No	No
02-1004	Tafoxiparin+Standard of Care	HEMA	37.2	36.2	37.4	35.2	.	.	.	.	33	24.7	36.7
02-1004	Tafoxiparin+Standard of Care	HEMA OR	.	.	.	Yes	.	.	.	.	.	Yes	.
02-1004	Tafoxiparin+Standard of Care	HEMA CS	.	.	.	No	.	.	.	.	.	No	.
02-1004	Tafoxiparin+Standard of Care	MCH	29.1	28.4	28.5	28.4	.	.	.	.	28.1	29.3	29
02-1004	Tafoxiparin+Standard of Care	MCV	89.3	84.9	85.4	86.5	.	.	.	.	83	86	89.7
02-1004	Tafoxiparin+Standard of Care	PLAT	129	118	96	100	.	.	.	.	61	94	218
02-1004	Tafoxiparin+Standard of Care	PLAT OR	Yes	Yes	Yes	Yes	.	.	.	.	Yes	Yes	.
02-1004	Tafoxiparin+Standard of Care	PLAT CS	No	No	Yes	Yes	.	.	.	.	Yes	Yes	.
02-1004	Tafoxiparin+Standard of Care	RBCC	4.17	4.26	4.38	4.07	.	.	.	.	3.98	2.87	4.09
02-1004	Tafoxiparin+Standard of Care	RBCC OR	.	.	.	.	.	.	.	.	Yes	Yes	.
02-1004	Tafoxiparin+Standard of Care	RBCC CS	.	.	.	.	.	.	.	.	No	No	.
02-1004	Tafoxiparin+Standard of Care	RETI	.	1.4	1.7	.	.	.	.	.	.	.	2.8
02-1004	Tafoxiparin+Standard of Care	RETI OR	.	.	.	.	.	.	.	.	.	.	Yes
02-1004	Tafoxiparin+Standard of Care	RETI CS	.	.	.	.	.	.	.	.	.	.	No
02-1004	Tafoxiparin+Standard of Care	WBCC	7.59	8.54	9.22	7.77	.	.	.	.	10.95	8.42	4.56
02-1004	Tafoxiparin+Standard of Care	WBCC OR	.	.	.	.	.	.	.	.	Yes	.	.
02-1004	Tafoxiparin+Standard of Care	WBCC CS	.	.	.	.	.	.	.	.	No	.	.
02-1005	Tafoxiparin+Standard of Care	HB	11.5	12.1	11.7	12.2	11.9	12	12.7	11.5	9.7	8.1	13
02-1005	Tafoxiparin+Standard of Care	HB OR	Yes	.	Yes	.	Yes	.	.	Yes	Yes	Yes	.

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”.**  
**The variable abbreviations are explained in Table .**  
**Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
02-1005	Tafoxiparin+Standard of Care	HB CS	No	.	No	.	No	.	.	No	No	No	.
02-1005	Tafoxiparin+Standard of Care	HEMA	34.9	37	35.2	36.3	36.6	35.8	38.3	35.1	28.8	24.4	40.8
02-1005	Tafoxiparin+Standard of Care	HEMA OR	Yes	.	Yes	.	.	Yes	.	Yes	Yes	Yes	.
02-1005	Tafoxiparin+Standard of Care	HEMA CS	No	.	No	.	.	No	.	No	No	No	.
02-1005	Tafoxiparin+Standard of Care	MCH	26	25.7	25.7	26.2	25.4	25.8	26.3	25.8	26.2	26.4	25.9
02-1005	Tafoxiparin+Standard of Care	MCH OR	.	Yes	Yes	.	Yes	Yes	.	Yes	.	.	Yes
02-1005	Tafoxiparin+Standard of Care	MCH CS	.	No	No	.	No	No	.	No	.	.	No
02-1005	Tafoxiparin+Standard of Care	MCV	78.8	78.4	77.1	78	78	77.1	79.3	78.7	77.6	79.8	81.4
02-1005	Tafoxiparin+Standard of Care	MCV OR	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	.
02-1005	Tafoxiparin+Standard of Care	MCV CS	No	No	No	No	No	No	No	No	No	No	.
02-1005	Tafoxiparin+Standard of Care	PLAT	278	250	240	217	256	258	253	224	276	236	265
02-1005	Tafoxiparin+Standard of Care	RBCC	4.42	4.72	4.56	4.65	4.69	4.64	4.83	4.46	3.71	3.07	5.02
02-1005	Tafoxiparin+Standard of Care	RBCC OR	.	.	.	.	.	.	.	.	Yes	Yes	.
02-1005	Tafoxiparin+Standard of Care	RBCC CS	.	.	.	.	.	.	.	.	No	No	.
02-1005	Tafoxiparin+Standard of Care	RETI	2.1	1.6	2.5	1.2	2.3	.	2.5	2	1.6	2.6	1.4
02-1005	Tafoxiparin+Standard of Care	RETI OR	.	.	Yes	.	Yes	.	Yes	.	.	Yes	.
02-1005	Tafoxiparin+Standard of Care	RETI CS	.	.	No	.	No	.	No	.	.	No	.
02-1005	Tafoxiparin+Standard of Care	WBCC	11.62	10.5	10.93	9.91	11.66	1200	13.97	11.4	17.79	9.71	8.93
02-1005	Tafoxiparin+Standard of Care	WBCC OR	Yes	.	Yes	.	Yes	Yes	Yes	Yes	Yes	.	.
02-1005	Tafoxiparin+Standard of Care	WBCC CS	No	.	No	.	No	No	No	No	No	.	.
02-1006	Tafoxiparin+Standard of Care	HB	12	11.3	.	12	12	11.8	11.7	12.4	11.4	.	13.2
02-1006	Tafoxiparin+Standard of Care	HB OR	.	Yes	.	.	.	Yes	Yes	.	Yes	.	.
02-1006	Tafoxiparin+Standard of Care	HB CS	.	No	.	.	.	No	No	.	No	.	.
02-1006	Tafoxiparin+Standard of Care	HEMA	37.2	34.6	.	36.1	36.3	36.4	35.4	38.5	34.6	.	78.5
02-1006	Tafoxiparin+Standard of Care	HEMA OR	.	Yes	.	.	.	.	Yes	.	Yes	.	.
02-1006	Tafoxiparin+Standard of Care	HEMA CS	.	No	.	.	.	.	No	.	No	.	.
02-1006	Tafoxiparin+Standard of Care	MCH	25.8	26.2	.	26.4	26.3	25.9	26.5	25.9	26	.	26
02-1006	Tafoxiparin+Standard of Care	MCH OR	Yes	.	.	.	.	Yes	.	.	.	.	.
02-1006	Tafoxiparin+Standard of Care	MCH CS	No	.	.	.	.	No	.	.	.	.	.
02-1006	Tafoxiparin+Standard of Care	MCV	80	80.4	.	79.3	79.4	80	80.3	80.5	79	.	78.5
02-1006	Tafoxiparin+Standard of Care	MCV OR	.	.	.	Yes	Yes	.	.	.	.	.	Yes
02-1006	Tafoxiparin+Standard of Care	MCV CS	.	.	.	No	No	.	.	.	.	.	No
02-1006	Tafoxiparin+Standard of Care	PLAT	221	196	.	212	124	148	173	186	159	.	189
02-1006	Tafoxiparin+Standard of Care	PLAT OR	.	.	.	.	Yes	Yes	.	.	.	.	.
02-1006	Tafoxiparin+Standard of Care	PLAT CS	.	.	.	.	No	No	.	.	.	.	.
02-1006	Tafoxiparin+Standard of Care	RBCC	4.65	4.3	.	4.55	4.57	4.56	4.41	4.78	4.38	.	5.02

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”.**  
**The variable abbreviations are explained in Table .**  
**Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
02-1006	Tafoxiparin+Standard of Care	RETI	2.8	.	.	2.6	2.9	2.8	3.1	3.6	.	.	1.8
02-1006	Tafoxiparin+Standard of Care	RETI OR	Yes	.	.	Yes	Yes	Yes	Yes	Yes	.	.	.
02-1006	Tafoxiparin+Standard of Care	RETI CS	No	.	.	No	No	No	No	No	.	.	.
02-1006	Tafoxiparin+Standard of Care	WBCC	9.81	7.49	.	7.86	7.72	8.06	7.46	7.56	8.01	.	7.06
02-1006	Tafoxiparin+Standard of Care	WBCC OR	.	.	.	.	.	.	.	.	.	.	.
02-1006	Tafoxiparin+Standard of Care	WBCC CS	.	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	HB	10.5	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	HB OR	Yes	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	HB CS	No	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	HEMA	32.2	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	MCH	30.9	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	MCV	94.7	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	PLAT	276	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	RBCC	3.4	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	RBCC OR	Yes	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	RBCC CS	No	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	RETI	2	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	WBCC	14.25	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	WBCC OR	Yes	.	.	.	.	.	.	.	.	.	.
02-1007	Not Randomised	WBCC CS	No	.	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	HB	10.9	9.4	.	.	.	.	.	.	.	.	12.1
02-1008	Standard of Care	HB OR	.	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	HB CS	.	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	HEMA	32.6	27.4	.	.	.	.	.	.	.	.	36.3
02-1008	Standard of Care	HEMA OR	.	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	HEMA CS	.	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	MCH	31.2	31.9	.	.	.	.	.	.	.	.	29
02-1008	Standard of Care	MCV	93.1	92.9	.	.	.	.	.	.	.	.	87.4
02-1008	Standard of Care	MCV OR	.	.	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	MCV CS	.	.	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	PLAT	156	167	.	.	.	.	.	.	.	.	252
02-1008	Standard of Care	RBCC	3.5	2.95	.	.	.	.	.	.	.	.	4.15
02-1008	Standard of Care	RBCC OR	Yes	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	RBCC CS	No	No	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	RETI	2.2	2.9	.	.	.	.	.	.	.	.	1.6
02-1008	Standard of Care	RETI OR	Yes	.	.	.	.	.	.	.	.	.	.

**Table 2 Haematology by variable and by subject. “CS” = Clinically Significant”, “OR = “Out of Normal Range”. The variable abbreviations are explained in Table . Data outside the reference range and assessed as clinically significant are marked in red.**

Subject	Group	Variable abbrev.	Visit										
			1	6	8	11	15	18	22	29	30	31	33
02-1008	Standard of Care	RETICS	No	.	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	WBCC	8.04	15.14	.	.	.	.	.	.	.	.	5.99
02-1008	Standard of Care	WBCC OR	.	Yes	.	.	.	.	.	.	.	.	.
02-1008	Standard of Care	WBCC CS	.	No	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	HB	12.1	.	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	HEMA	36	.	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	MCH	28.5	.	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	MCV	84.6	.	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	PLAT	206	.	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	RBCC	4.25	.	.	.	.	.	.	.	.	.	.
02-1010	Tafoxiparin+Standard of Care	WBCC	10.64	.	.	.	.	.	.	.	.	.	.

### Safety Summary and Conclusions

No SAEs reported in the study. No safety concern was raised.